Cargando…

Focal therapy for localized prostate cancer: is there a “middle ground” between active surveillance and definitive treatment?

In recent years, it has come a long way in the diagnosis, treatment, and follow-up of prostate cancer. Beside this, it was argued that definitive treatments could cause overtreatment, particularly in the very low, low, and favorable risk group. When alternative treatment and follow-up methods are be...

Descripción completa

Detalles Bibliográficos
Autores principales: Demirel, Cihan H, Altok, Muammer, Davis, John W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6337958/
https://www.ncbi.nlm.nih.gov/pubmed/30178774
http://dx.doi.org/10.4103/aja.aja_64_18
_version_ 1783388369752948736
author Demirel, Cihan H
Altok, Muammer
Davis, John W
author_facet Demirel, Cihan H
Altok, Muammer
Davis, John W
author_sort Demirel, Cihan H
collection PubMed
description In recent years, it has come a long way in the diagnosis, treatment, and follow-up of prostate cancer. Beside this, it was argued that definitive treatments could cause overtreatment, particularly in the very low, low, and favorable risk group. When alternative treatment and follow-up methods are being considered for this group of patients, active surveillance is seen as a good alternative for patients with very low and low-risk groups in this era. However, it has become necessary to find other alternatives for patients in the favorable risk group or patients who cannot adopt active follow-up. In the light of technological developments, the concept of focal therapy was introduced with the intensification of research to treat only the lesioned area instead of treating the entire organ for prostate lesions though there are not many publications about many of them yet. According to the initial results, it was understood that the results could be good if the appropriate focal therapy technique was applied to the appropriate patient. Thus, focal therapies have begun to find their “middle ground” place between definitive therapies and active follow-up.
format Online
Article
Text
id pubmed-6337958
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-63379582019-02-14 Focal therapy for localized prostate cancer: is there a “middle ground” between active surveillance and definitive treatment? Demirel, Cihan H Altok, Muammer Davis, John W Asian J Androl Invited Review In recent years, it has come a long way in the diagnosis, treatment, and follow-up of prostate cancer. Beside this, it was argued that definitive treatments could cause overtreatment, particularly in the very low, low, and favorable risk group. When alternative treatment and follow-up methods are being considered for this group of patients, active surveillance is seen as a good alternative for patients with very low and low-risk groups in this era. However, it has become necessary to find other alternatives for patients in the favorable risk group or patients who cannot adopt active follow-up. In the light of technological developments, the concept of focal therapy was introduced with the intensification of research to treat only the lesioned area instead of treating the entire organ for prostate lesions though there are not many publications about many of them yet. According to the initial results, it was understood that the results could be good if the appropriate focal therapy technique was applied to the appropriate patient. Thus, focal therapies have begun to find their “middle ground” place between definitive therapies and active follow-up. Medknow Publications & Media Pvt Ltd 2019 2018-08-31 /pmc/articles/PMC6337958/ /pubmed/30178774 http://dx.doi.org/10.4103/aja.aja_64_18 Text en Copyright: © The Author(s)(2018) http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Invited Review
Demirel, Cihan H
Altok, Muammer
Davis, John W
Focal therapy for localized prostate cancer: is there a “middle ground” between active surveillance and definitive treatment?
title Focal therapy for localized prostate cancer: is there a “middle ground” between active surveillance and definitive treatment?
title_full Focal therapy for localized prostate cancer: is there a “middle ground” between active surveillance and definitive treatment?
title_fullStr Focal therapy for localized prostate cancer: is there a “middle ground” between active surveillance and definitive treatment?
title_full_unstemmed Focal therapy for localized prostate cancer: is there a “middle ground” between active surveillance and definitive treatment?
title_short Focal therapy for localized prostate cancer: is there a “middle ground” between active surveillance and definitive treatment?
title_sort focal therapy for localized prostate cancer: is there a “middle ground” between active surveillance and definitive treatment?
topic Invited Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6337958/
https://www.ncbi.nlm.nih.gov/pubmed/30178774
http://dx.doi.org/10.4103/aja.aja_64_18
work_keys_str_mv AT demirelcihanh focaltherapyforlocalizedprostatecanceristhereamiddlegroundbetweenactivesurveillanceanddefinitivetreatment
AT altokmuammer focaltherapyforlocalizedprostatecanceristhereamiddlegroundbetweenactivesurveillanceanddefinitivetreatment
AT davisjohnw focaltherapyforlocalizedprostatecanceristhereamiddlegroundbetweenactivesurveillanceanddefinitivetreatment